Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare Inc. (Nasdaq: IXHL) reported fiscal full year 2024 financial results and business updates. Key highlights include:
1. Strategic financing with Arena Investors, providing access to up to $59.0 million USD.
2. Positive top-line results from Phase 2 proof-of-concept clinical trial of PSX-001 for generalized anxiety disorder.
3. Commenced dosing in RePOSA Phase 2/3 clinical trial of IHL-42X for obstructive sleep apnea.
4. Received FDA clearance for PsiGAD2, a Phase 2 clinical trial of PSX-001.
5. Completed redomiciliation to the United States and listed on Nasdaq under ticker IXHL.
Financial results: G&A expenses increased to $17.2 million USD, R&D expenses rose to $12.9 million USD, and net loss was $18.5 million USD for the fiscal year ended June 30, 2024. Cash and cash equivalents were $5.9 million USD as of June 30, 2024.
Incannex Healthcare (Nasdaq: IXHL) has secured a strategic financing deal with Arena Investors for up to $60 million. The agreement includes up to $10 million in secured convertible notes and a $50 million equity line of credit (ELOC). The initial funding tranche of $3.33 million will be received upon closing, with two subsequent tranches available up to $6.67 million. The ELOC allows Incannex to issue and sell up to $50 million of common stock over 36 months.
Incannex plans to use the funds to support ongoing clinical trials of its proprietary drug candidates, including IHL-42X for obstructive sleep apnea, PsiGAD for generalized anxiety disorder, and IHL-675A for rheumatoid arthritis. This financing strengthens Incannex's ability to advance its lead programs through key late-stage clinical milestones.
Incannex Healthcare Inc. (Nasdaq: IXHL) has received FDA approval to conduct a Phase 2 clinical trial for its psilocybin-assisted psychotherapy in patients with Generalised Anxiety Disorder. The trial, named PsiGAD2, will involve approximately 94 patients and follows the successful PsiGAD1 proof-of-concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Scale (HAM-A) score.
The study will evaluate two dose strengths of PSX-001, Incannex's psilocybin formulation, in a double-blind setting. The primary endpoint is the change in HAM-A score two weeks after the second dosing session, with additional endpoints including quality of life measures and safety assessments. The trial is also under review by the UK's MHRA for concurrent implementation in the United Kingdom.
Incannex Healthcare (Nasdaq: IXHL) has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial for its proprietary sleep apnea drug candidate. The study involved 115 participants who completed four treatment periods, comparing IHL-42X to FDA reference listed drugs Marinol and Taro acetazolamide. No serious adverse events were reported during the study.
IHL-42X, a fixed dose combination of dronabinol and acetazolamide, targets obstructive sleep apnea (OSA), a condition affecting millions in the USA with no registered pharmaceutical treatment. The trial's data will be analyzed to generate comparative pharmacokinetic profiles, potentially allowing Incannex to rely on existing safety and toxicology data for future regulatory submissions.
Concurrently, the Phase 2/3 FDA IND-enabling RePOSA clinical trial for IHL-42X continues, having commenced dosing in May 2024.
Incannex Healthcare has commenced patient dosing in its Phase 2/3 RePOSA clinical trial to assess the safety and efficacy of IHL-42X in treating obstructive sleep apnea (OSA). This trial is significant as it follows a successful Phase 2A study that showed a greater than 50% reduction in the apnea hypopnea index (AHI) at low doses, with 25% of patients achieving over 80% reduction. The trial will span 52 weeks, involving 560 patients across the US, EU, and UK, and aims to provide an alternative to CPAP machines which many patients find intolerable. If successful, IHL-42X could address a large unmet medical need and create substantial commercial and shareholder value.
Incannex Healthcare Inc. (Nasdaq: IXHL) successfully completed a pre-IND meeting with the FDA for CannQuit-O, a treatment for Opioid Use Disorder. The FDA provided recommendations on the clinical development strategy, patient populations, efficacy endpoints, and safety monitoring. This milestone marks progress towards opening an IND for the product.
Stonegate Healthcare Partners has released a report on potentially transformative therapies for Generalized Anxiety Disorder (GAD), aiming to improve patients' quality of life. The report highlights leading programs by companies like Mindmed, Incannex (NASDAQ: IXHL), and Compass Pathways. The global market for GAD treatment is projected to exceed $4 billion by 2033, with a 9% CAGR from 2023 onwards.
Summary not available.
Summary not available.
Summary not available.